{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-052377","form_type":"8-K","ticker":"PHGE","cik":"0001739174","company_name":"BiomX Inc.","filed_at":"2025-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.526525+00:00","generated_at":"2026-05-19T17:19:38.260849+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"BiomX posts updated corporate presentation; no material new disclosures","bullets":["Posted updated slide deck in Investors section of website on June 9, 2025.","Presentation titled 'Clinical Stage Programs Addressing Urgent Need for Overcoming Antibiotic Resistance'.","No specific financial data, guidance changes, or clinical milestones disclosed in the filing.","Filed under Regulation FD; company undertakes no obligation to update the materials."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-052377","json":"https://secwatch.observer/filing/0001213900-25-052377.json","markdown":"https://secwatch.observer/filing/0001213900-25-052377.md","text":"https://secwatch.observer/filing/0001213900-25-052377.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739174/000121390025052377/0001213900-25-052377-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739174/000121390025052377/ea0245109-8k_biomxinc.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T17:19:38.260849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}